Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis
Annals of the Rheumatic Diseases · 2025-11 · 84 (11) · 1888-1899
DOI: 10.1016/j.ard.2025.06.2131 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2025-11. Verfasst von Peter A Merkel und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: pmerkel@upenn.edu. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Churg-Strauss Syndrome, Receptors, Interleukin-5, Granulomatosis with Polyangiitis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: pmerkel@upenn.edu.
- Department of Medicine, McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Université Paris Cité, Paris, France.
- Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany.
- Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France.
- Department of Medicine, University of Cambridge, Cambridge, UK.
Förderung
- AstraZeneca
Zitieren
APA
Merkel, P. A., Nair, P. K., Khalidi, N., Terrier, B., Hellmich, B., Bourdin, A., Jayne, D. R. W., Jackson, D. J., Roufosse, F., Pagnoux, C., Specks, U., Börjesson Sjö, L., Ho, C. N., Jison, M., McCrae, C., Necander, S., Rodríguez-Suárez, E., Shavit, A., Walton, C., …, & MANDARA Study Group (2025). Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Annals of the Rheumatic Diseases, 84(11), 1888-1899. https://doi.org/10.1016/j.ard.2025.06.2131
Vancouver
Merkel PA, Nair PK, Khalidi N, Terrier B, Hellmich B, Bourdin A, et al. Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Annals of the Rheumatic Diseases. 2025;84(11):1888-1899. doi:10.1016/j.ard.2025.06.2131
BibTeX
@article{Merkel2025,
author = {Merkel, Peter A and Nair, Parameswaran K and Khalidi, Nader and Terrier, Benjamin and Hellmich, Bernhard and Bourdin, Arnaud and Jayne, David R W and Jackson, David J and Roufosse, Florence and Pagnoux, Christian and Specks, Ulrich and Börjesson Sjö, Lena and Ho, Calvin N and Jison, Maria and McCrae, Christopher and Necander, Sofia and Rodríguez-Suárez, Eva and Shavit, Anat and Walton, Claire and Wechsler, Michael E and MANDARA Study Group, MANDARA Study Group},
title = {Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
number = {11},
pages = {1888--1899},
doi = {10.1016/j.ard.2025.06.2131}
}
EUVIMED